⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 15, 2024Open Access

Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Timothy A. Yap Anthony W. Tolcher Ruth Plummer Jatinder Kaur Mukker Marta Enderlin Christine Hicking Thomas Grombacher Giuseppe Locatelli Zoltán Szűcs Ioannis Gounaris Johann S. de Bono

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S1. Tuvusertib in vivo activity in ATM- and ARID1A-mutated xenograft models in mice

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yap et al. (2024) studied this question.

synapsesocial.com/papers/68e6a14db6db643587624ff6 https://doi.org/10.1158/1078-0432.25826660.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
2Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
3Supplementary Figure S2 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
4Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024
5Supplementary Figure S4 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors2024